ArticleWorld journal of gastrointestinal oncology2025
Rapid cholestasis improvement as key strategy for steroid-refractory immune-related cholangitis: A case report.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteroid-refractory immune-related cholangitis, characterized by biliary obstruction, can be caused by drugs such as immune checkpoint inhibitors (ICIs). While there a few reports of sclerosing cholangitis after ICI administration, the therapeutic importance of local relief of obstruction has not been reported. CASE SUMMARY: A 60-year-old female patient with biliary tract carcinoma and peritoneal metastasis developed elevated liver enzymes following four cycles of combined therapy with anti-PD-1 (Pembrolizumab) and a tyrosine kinase inhibitor. Magnetic resonance cholangiopancreatography indicated a thickening of the upper bile duct and pancreatic sections with narrow lumens. Digital peroral cholangioscopy revealed several erosions and surface vessel tortuosities coating the common bile duct. Endoscopic ultrasound revealed disruption of the middle lumen segment, with poorly defined wall structures. Endoscopic retrograde cholangiopancreatography (ERCP) demonstrated mucosal irregularities with tortuous surface vessels along the common bile duct. Angiographic imaging revealed irregular defects in the middle and lower common bile duct segments, while the proximal duct exhibited multifocal stenosis alternating with dilatation. Biopsy samples obtained
conclusionStent placement offers prompt alleviation of cholestasis and constitutes an effective therapeutic strategy for managing immune-related cholangitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.